Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics

Miriam Marqués1, Amit Kumar, Isabel Cortés

  • 1Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin 3, Cantoblanco, Madrid E-28049, Spain.

Insights

Phosphoinositide 3-kinase (PI3K) isoforms p110alpha and p110beta regulate cell cycle entry. p110alpha activates early in G(0)/G(1), while p110beta peaks in late G(1), with both controlling S-phase entry.

Area of Science:

  • Cell Biology
  • Molecular Signaling

Background:

  • Phosphoinositide 3-kinase (PI3K) is crucial for cell growth and cycle progression.
  • Two PI3K isoforms, p110alpha and p110beta, are vital for embryonic development and cell division.

Purpose of the Study:

  • To determine the specific activation timing of PI3K p110alpha and p110beta during the cell cycle.
  • To investigate whether both isoforms regulate entry into S-phase.

Main Methods:

  • Analysis of PI3K isoform activation kinetics during G(0)/G(1) and late G(1) phases.
  • Investigating the upstream activators (tyrosine kinases, Ras) for each isoform.
  • Assessing the impact of isoform inhibition on downstream effectors and cell cycle progression.

Main Results:

  • p110alpha is activated first in G(0)/G(1), followed by a minor p110beta peak.
  • In late G(1), p110alpha activation precedes p110beta, which shows maximum activity.
  • p110beta activation requires Ras, while p110alpha is activated by tyrosine kinases and subsequently by Ras.
  • Inhibition of either isoform reduced cell cycle entry, with p110alpha selectively affecting early G(1) events.

Conclusions:

  • PI3K p110alpha and p110beta exhibit distinct activation requirements and kinetics within the G(1) phase.
  • p110alpha plays a selective role in the G(0)/G(1) transition.
  • Both PI3K p110alpha and p110beta are essential regulators of S-phase entry.

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...